Skribe is a wearable cardio-oncology platform designed to assess cardiac function – beginning with LVEF – in minutes, helping oncologists screen for cardiotoxicity and keep life-saving treatments on schedule
Delays in cancer treatment can be the difference between life and death, but
side effects can be deadly too – especially when they involve the heart.
For many patients, heart screening is an essential part of cancer treatment, but imaging bottlenecks, referral delays, and unanswered cardiac questions regularly force oncologists to delay care.
Skribe empowers oncologists with the ability to assess cardiac function, beginning with LVEF, in minutes in the clinic or at home.
What if protecting the heart was as easy as putting on a patch?
Skribe’s Resonant Body Power system enables a battery-free sensor design for maximum comfort – without sacrificing clinical accuracy.
Resonant Body Power allows Skribe’s patch to harvest energy from a smartwatch, eliminating bulk and discomfort.
With its minimal, flexible form factor, the Skribe patch can be placed
where health signals are strongest, elminating the tradeoff between comfort and data quality.
Skribe is focused on giving doctors actionable insights to streamline patient care - not mountains of hard-to-interpret data
The same technology designed to help keep cancer care on schedule may also support cardiac safety monitoring in oncology trials.
Skribe enables fast, participant-friendly cardiac assessments that may
help sponsors detect cardiotoxicity signals earlier and collect richer
physiologic datasets.
